DeepInfra | $107,000,000 | (May 5, 2026)
Kibu, Inc | $10,500,000 | (May 5, 2026)
Fun | $72,000,000 | (May 5, 2026)
Certified by Founder
Lodge
Deverra Therapeutics
start up
United States
- Seattle
- 20/09/2023
- Unknown
- $2,400,000
Deverra Therapeutics is a clinical stage biotechnology company dedicated to the development of allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company has an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and data from 5 clinical trials. This platform can be used to generate a range of unmodified and modified immune cells to treat patients with cancer and infectious diseases.
- Industry Biotechnology
- Website https://www.deverratx.com/
- LinkedIn https://www.linkedin.com/company/deverra-therapeutics/about/
Panthalassa | $140,000,000 | (May 5, 2026)
Featherless AI | $20,000,000 | (May 5, 2026)
Healthfab | $2,100,000 | (May 5, 2026)
LakeFusion | $7,500,000 | (May 5, 2026)
Enzo Health | $20,000,000 | (May 5, 2026)
Barocal | $10,000,000 | (May 5, 2026)
Zapdos Labs | $500,000 | (May 5, 2026)
Blomma | $5,000,000 | (May 1, 2026)
Dreambase | $3,700,000 | (May 1, 2026)